1. ^ A vitamin/nutriceutical formulation improves memory and cognitive performance in community-dwelling adults without dementia.
  2. ^ Efficacy of a vitamin/nutriceutical formulation for moderate-stage to later-stage Alzheimer’s disease: a placebo-controlled pilot study.
  3. ^ Efficacy of a vitamin/nutriceutical formulation for early-stage Alzheimer’s disease: a 1-year, open-label pilot study with an 16-month caregiver extension.
  4. a b c S-Adenosylmethionine (Ademetionine) in Psychiatric Disorders: Historical Perspective and Current Status.
  5. a b Bottiglieri T, et al. Homocysteine, folate, methylation, and monoamine metabolism in depressionJ Neurol Neurosurg Psychiatry. (2000)
  6. a b c d Loehrer FM, et al. Influence of oral S-adenosylmethionine on plasma 5-methyltetrahydrofolate, S-adenosylhomocysteine, homocysteine and methionine in healthy humansJ Pharmacol Exp Ther. (1997)
  7. a b c d Thompson MA, et al. Dietary supplement S-adenosyl-L-methionine (AdoMet) effects on plasma homocysteine levels in healthy human subjects: a double-blind, placebo-controlled, randomized clinical trialJ Altern Complement Med. (2009)
  8. ^ Struys EA, et al. Determination of S-adenosylmethionine and S-adenosylhomocysteine in plasma and cerebrospinal fluid by stable-isotope dilution tandem mass spectrometryClin Chem. (2000)
  9. a b Bell KM, et al. S-adenosylmethionine blood levels in major depression: changes with drug treatmentActa Neurol Scand Suppl. (1994)
  10. ^ Shippy RA, et al. S-adenosylmethionine (SAM-e) for the treatment of depression in people living with HIV/AIDSBMC Psychiatry. (2004)
  11. ^ S-Adenosylmethionine Levels in the Diagnosis of Pneumocystis carinii Pneumonia in Patients with HIV Infection.
  12. a b c Bottiglieri T, et al. Cerebrospinal fluid S-adenosylmethionine in depression and dementia: effects of treatment with parenteral and oral S-adenosylmethionineJ Neurol Neurosurg Psychiatry. (1990)
  13. ^ Poirier LA, et al. Blood S-adenosylmethionine concentrations and lymphocyte methylenetetrahydrofolate reductase activity in diabetes mellitus and diabetic nephropathyMetabolism. (2001)
  14. ^ Maj M, Zizolfi S, Del Vecchio M. Blood levels of S-adenosylmethionine in unmedicated schizophrenic and depressive patientsNeuropsychobiology. (1981)
  15. ^ Andreoli VM, Maffei F, Tonon GC. S-adenosyl-L-methionine (SAMe) blood levels in schizophrenia and depressionMonogr Gesamtgeb Psychiatr Psychiatry Ser. (1978)
  16. a b c d Strous RD, et al. Improvement of aggressive behavior and quality of life impairment following S-adenosyl-methionine (SAM-e) augmentation in schizophreniaEur Neuropsychopharmacol. (2009)
  17. ^ Stabler SP, et al. Elevated serum S-adenosylhomocysteine in cobalamin-deficient elderly and response to treatmentAm J Clin Nutr. (2006)
  18. ^ Poirier LA, et al. Blood determinations of S-adenosylmethionine, S-adenosylhomocysteine, and homocysteine: correlations with dietCancer Epidemiol Biomarkers Prev. (2001)
  19. ^ Stramentinoli G. Pharmacologic aspects of S-adenosylmethionine. Pharmacokinetics and pharmacodynamicsAm J Med. (1987)
  20. a b c Silveri MM, et al. S-adenosyl-L-methionine: effects on brain bioenergetic status and transverse relaxation time in healthy subjectsBiol Psychiatry. (2003)
  21. ^ Dunne JB, et al. Evidence that S-adenosyl-L-methionine diastereoisomers may reduce ischaemia-reperfusion injury by interacting with purinoceptors in isolated rat liverBr J Pharmacol. (1998)
  22. ^ Hoffman JL. Chromatographic analysis of the chiral and covalent instability of S-adenosyl-L-methionineBiochemistry. (1986)
  23. ^ Lee S, et al. Steric Course of the Methyl Transfer from AdoMet to S-Farnesyl-3-thiopropionate by G-Protein MethyltransferaseJ Org Chem. (1998)
  24. ^ Kealey JT, et al. Stereochemistry of methyl transfer catalyzed by tRNA (m5U54)-methyltransferase–evidence for a single displacement mechanismNucleic Acids Res. (1991)
  25. ^ Woodard RW, et al. Stereochemical course of the transmethylation catalyzed by catechol O-methyltransferaseJ Biol Chem. (1980)
  26. ^ Borchardt RT, Wu YS. Potential inhibitors of S-adenosylmethionine-dependent methyltransferases. 5. Role of the asymmetric sulfonium pole in the enzymatic binding of S-adenosyl-L-methionineJ Med Chem. (1976)
  27. a b c Najm WI, et al. S-adenosyl methionine (SAMe) versus celecoxib for the treatment of osteoarthritis symptoms: a double-blind cross-over trial. {ISRCTN36233495}BMC Musculoskelet Disord. (2004)
  28. a b McMillan JM, Walle UK, Walle T. S-adenosyl-L-methionine: transcellular transport and uptake by Caco-2 cells and hepatocytesJ Pharm Pharmacol. (2005)
  29. a b c d e Yang J, et al. Pharmacokinetic properties of S-adenosylmethionine after oral and intravenous administration of its tosylate disulfate salt: a multiple-dose, open-label, parallel-group study in healthy Chinese volunteersClin Ther. (2009)
  30. a b Giulidori P, et al. Pharmacokinetics of S-adenosyl-L-methionine in healthy volunteersEur J Clin Pharmacol. (1984)
  31. a b Agrimi G, et al. Identification of the human mitochondrial S-adenosylmethionine transporter: bacterial expression, reconstitution, functional characterization and tissue distributionBiochem J. (2004)
  32. ^ Dridi L, Ahmed Ouameur A, Ouellette M. High affinity S-Adenosylmethionine plasma membrane transporter of Leishmania is a member of the folate biopterin transporter (FBT) familyJ Biol Chem. (2010)
  33. ^ Horne DW, Holloway RS, Wagner C. Transport of S-adenosylmethionine in isolated rat liver mitochondriaArch Biochem Biophys. (1997)
  34. ^ Williams AC, Ramsden DB. Nicotinamide homeostasis: a xenobiotic pathway that is key to development and degenerative diseasesMed Hypotheses. (2005)
  35. ^ Pavia J, et al. Effect of S-adenosyl methionine on muscarinic receptors in young ratsLife Sci. (1997)
  36. ^ Muccioli G, et al. Effect of S-adenosyl-L-methionine on brain muscarinic receptors of aged ratsEur J Pharmacol. (1992)
  37. a b Chan A, et al. Dietary and genetic compromise in folate availability reduces acetylcholine, cognitive performance and increases aggression: critical role of S-adenosyl methionineJ Nutr Health Aging. (2008)
  38. ^ Shea TB, Chan A. S-adenosyl methionine: a natural therapeutic agent effective against multiple hallmarks and risk factors associated with Alzheimer’s diseaseJ Alzheimers Dis. (2008)
  39. ^ Fava M, et al. Folate, vitamin B12, and homocysteine in major depressive disorderAm J Psychiatry. (1997)
  40. ^ Alpert JE, et al. Nutrition and depression: focus on folateNutrition. (2000)
  41. ^ Bottiglieri T, et al. Transmethylation in depressionAla J Med Sci. (1988)
  42. ^ Matthysse S, Baldessarini RJ. S-adenosylmethionine and catechol-O-methyl-transferase in schizophreniaAm J Psychiatry. (1972)
  43. ^ Tolbert LC. MAT kinetics in affective disorders and schizophrenia. An accountAla J Med Sci. (1988)
  44. ^ Bressa GM. S-adenosyl-l-methionine (SAMe) as antidepressant: meta-analysis of clinical studiesActa Neurol Scand Suppl. (1994)
  45. ^ Saletu-Zyhlarz GM, et al. Visualizing central effects of S-adenosyl-L-methionine (SAMe), a natural molecule with antidepressant properties, by pharmaco-EEG mappingInt J Neuropsychopharmacol. (2002)
  46. ^ Role of S-adenosyl-L-methionine in the treatment of depression: a review of the evidence.
  47. ^ Fava M, et al. Rapidity of onset of the antidepressant effect of parenteral S-adenosyl-L-methioninePsychiatry Res. (1995)
  48. ^ Berlanga C, et al. Efficacy of S-adenosyl-L-methionine in speeding the onset of action of imipraminePsychiatry Res. (1992)
  49. a b Papakostas GI, et al. S-adenosyl methionine (SAMe) augmentation of serotonin reuptake inhibitors for antidepressant nonresponders with major depressive disorder: a double-blind, randomized clinical trialAm J Psychiatry. (2010)
  50. ^ Fleisch SB, Travis MJ, Ryan ND. Discrepancy in response and remission rates for SAMe-treated patients in a double-blind, randomized clinical trialAm J Psychiatry. (2010)
  51. ^ Alpert JE, et al. S-adenosyl-L-methionine (SAMe) as an adjunct for resistant major depressive disorder: an open trial following partial or nonresponse to selective serotonin reuptake inhibitors or venlafaxineJ Clin Psychopharmacol. (2004)
  52. a b Sarris J1, et al. S-adenosyl methionine (SAMe) versus escitalopram and placebo in major depression RCT: efficacy and effects of histamine and carnitine as moderators of responseJ Affect Disord. (2014)
  53. ^ Strous RD, et al. Aggressive behavior in schizophrenia is associated with the low enzyme activity COMT polymorphism: a replication studyAm J Med Genet B Neuropsychiatr Genet. (2003)
  54. ^ Strous RD, et al. Analysis of a functional catechol-O-methyltransferase gene polymorphism in schizophrenia: evidence for association with aggressive and antisocial behaviorPsychiatry Res. (1997)
  55. ^ Di Rocco A, et al. S-Adenosyl-Methionine improves depression in patients with Parkinson’s disease in an open-label clinical trialMov Disord. (2000)
  56. a b Levkovitz Y, et al. Effects of S-adenosylmethionine augmentation of serotonin-reuptake inhibitor antidepressants on cognitive symptoms of major depressive disorderJ Affect Disord. (2012)
  57. ^ Arnold O, et al. Double-blind, placebo-controlled pharmacodynamic studies with a nutraceutical and a pharmaceutical dose of ademetionine (SAMe) in elderly subjects, utilizing EEG mapping and psychometryEur Neuropsychopharmacol. (2005)
  58. a b c Spijkerman AM, et al. S-adenosylmethionine and 5-methyltetrahydrofolate are associated with endothelial function after controlling for confounding by homocysteine: the Hoorn StudyArterioscler Thromb Vasc Biol. (2005)
  59. ^ Prognostic Impact of Coronary Vasodilator Dysfunction on Adverse Long-Term Outcome of Coronary Heart Disease.
  60. ^ Mischoulon D, et al. Bioavailability of S-adenosyl methionine and impact on response in a randomized, double-blind, placebo-controlled trial in major depressive disorderJ Clin Psychiatry. (2012)
  61. ^ Gören JL, et al. Bioavailability and lack of toxicity of S-adenosyl-L-methionine (SAMe) in humansPharmacotherapy. (2004)
  62. ^ Tavoni A, et al. Evaluation of S-adenosylmethionine in primary fibromyalgia. A double-blind crossover studyAm J Med. (1987)
  63. ^ Volkmann H, et al. Double-blind, placebo-controlled cross-over study of intravenous S-adenosyl-L-methionine in patients with fibromyalgiaScand J Rheumatol. (1997)
  64. a b Jacobsen S, Danneskiold-Samsøe B, Andersen RB. Oral S-adenosylmethionine in primary fibromyalgia. Double-blind clinical evaluationScand J Rheumatol. (1991)
  65. ^ Goldenberg DL. Pharmacological treatment of fibromyalgia and other chronic musculoskeletal painBest Pract Res Clin Rheumatol. (2007)
  66. ^ Kalhan SC, et al. Methionine and protein metabolism in non-alcoholic steatohepatitis: evidence for lower rate of transmethylation of methionineClin Sci (Lond). (2011)
  67. ^ Loguercio C, et al. Effect of S-adenosyl-L-methionine administration on red blood cell cysteine and glutathione levels in alcoholic patients with and without liver diseaseAlcohol Alcohol. (1994)
  68. ^ Chawla RK, et al. Plasma cysteine, cystine, and glutathione in cirrhosisGastroenterology. (1984)
  69. ^ Yuan L, Kaplowitz N. Glutathione in liver diseases and hepatotoxicityMol Aspects Med. (2009)
  70. a b Mato JM, et al. S-adenosylmethionine in alcoholic liver cirrhosis: a randomized, placebo-controlled, double-blind, multicenter clinical trialJ Hepatol. (1999)
  71. ^ Santini D, et al. S-adenosylmethionine (AdoMet) supplementation for treatment of chemotherapy-induced liver injuryAnticancer Res. (2003)
  72. ^ Binder T, et al. Randomized prospective comparative study of ursodeoxycholic acid and S-adenosyl-L-methionine in the treatment of intrahepatic cholestasis of pregnancyJ Perinat Med. (2006)
  73. ^ Roncaglia N, et al. A randomised controlled trial of ursodeoxycholic acid and S-adenosyl-l-methionine in the treatment of gestational cholestasisBJOG. (2004)
  74. ^ Nicastri PL, et al. A randomised placebo-controlled trial of ursodeoxycholic acid and S-adenosylmethionine in the treatment of intrahepatic cholestasis of pregnancyBr J Obstet Gynaecol. (1998)
  75. ^ Floreani A, et al. S-adenosylmethionine versus ursodeoxycholic acid in the treatment of intrahepatic cholestasis of pregnancy: preliminary results of a controlled trialEur J Obstet Gynecol Reprod Biol. (1996)
  76. ^ Ribalta J, et al. S-adenosyl-L-methionine in the treatment of patients with intrahepatic cholestasis of pregnancy: a randomized, double-blind, placebo-controlled study with negative resultsHepatology. (1991)
  77. a b Duong FH, et al. S-Adenosylmethionine and betaine correct hepatitis C virus induced inhibition of interferon signaling in vitroHepatology. (2006)
  78. ^ Duong FH, et al. Hepatitis C virus inhibits interferon signaling through up-regulation of protein phosphatase 2AGastroenterology. (2004)
  79. ^ Duong FH, et al. Upregulation of protein phosphatase 2Ac by hepatitis C virus modulates NS3 helicase activity through inhibition of protein arginine methyltransferase 1J Virol. (2005)
  80. ^ Filipowicz M, et al. S-adenosyl-methionine and betaine improve early virological response in chronic hepatitis C patients with previous nonresponsePLoS One. (2010)
  81. ^ Feld JJ, et al. S-adenosyl methionine improves early viral responses and interferon-stimulated gene induction in hepatitis C nonrespondersGastroenterology. (2011)
  82. ^ Medici V, et al. S-adenosyl-L-methionine treatment for alcoholic liver disease: a double-blinded, randomized, placebo-controlled trialAlcohol Clin Exp Res. (2011)
  83. a b c Caruso I, Pietrogrande V. Italian double-blind multicenter study comparing S-adenosylmethionine, naproxen, and placebo in the treatment of degenerative joint diseaseAm J Med. (1987)
  84. a b Witte S, Lasek R, Victor N. Meta-analysis of the efficacy of adenosylmethionine and oxaceprol in the treatment of osteoarthritisOrthopade. (2002)
  85. a b c d Soeken KL, et al. Safety and efficacy of S-adenosylmethionine (SAMe) for osteoarthritisJ Fam Pract. (2002)
  86. ^ di Padova C. S-adenosylmethionine in the treatment of osteoarthritis. Review of the clinical studiesAm J Med. (1987)
  87. a b Kim J, et al. Comparative clinical trial of S-adenosylmethionine versus nabumetone for the treatment of knee osteoarthritis: an 8-week, multicenter, randomized, double-blind, double-dummy, Phase IV study in Korean patientsClin Ther. (2009)
  88. ^ Papadopoulos V, et al. Effects of the transmethylation inhibitor S-adenosyl-homocysteine and of the methyl donor S-adenosyl-methionine on rat Leydig cell function in vitroJ Steroid Biochem. (1987)
  89. ^ Manteuffel-Cymborowska M, Chmurzynska W, Grzelakowska-Sztabert B. Tissue-specific effects of testosterone on S-adenosylmethionine formation and utilization in the mouseBiochim Biophys Acta. (1992)
  90. ^ Heljasvaara R, et al. Transgenic mice overexpressing ornithine and S-adenosylmethionine decarboxylases maintain a physiological polyamine homoeostasis in their tissuesBiochem J. (1997)
  91. ^ Crozat A, et al. Comparison of androgen regulation of ornithine decarboxylase and S-adenosylmethionine decarboxylase gene expression in rodent kidney and accessory sex organsEndocrinology. (1992)
  92. ^ Fjösne HE, Strand H, Sunde A. Dose-dependent induction of ornithine decarboxylase and S-adenosyl-methionine decarboxylase activity by testosterone in the accessory sex organs of male ratsProstate. (1992)
  93. ^ de las Heras MA, Calandra RS. S-adenosyl-L-methionine decarboxylase activity in the rat epididymis: ontogeny and androgenic controlJ Androl. (1991)
  94. ^ Müller T, Fowler B, Kuhn W. Levodopa intake increases plasma levels of S-adenosylmethionine in treated patients with Parkinson diseaseClin Neuropharmacol. (2005)
  95. ^ Kagan BL, et al. Oral S-adenosylmethionine in depression: a randomized, double-blind, placebo-controlled trialAm J Psychiatry. (1990)